In our randomized controlled and blinded trial, we demonstrated that microglial loss of TAK1 leads to a reduction of infarct volumes, decreased neurological deficits, and an attenuated apoptosis rate in the peri-infarct-zone 72 h after stroke. Here, MAP3K7 is linked to Stroke.